- 3 days ago
- 11 min read
Why This Data Matters Right Now
If you or someone you love has relapsed or refractory multiple myeloma, you've probably already heard the term BCMA CAR-T. What you may not know is that China has quietly become one of the most important places in the world for this therapy.
A 2025 analysis published in Discover Oncology confirmed something significant: domestically developed BCMA CAR-T cell therapies in China are now delivering <cite index="1-1">overall response rates of 79–89% in B-cell malignancies and a 64% progression-free survival rate at 12 months in multiple myeloma</cite>. That's not a lab result. That's real clinical performance, at scale, inside one of the largest cancer-treatment systems on earth.a
This matters for three reasons:
It signals durability. A 64% 12-month PFS means roughly two out of three patients are still alive without disease progression a full year after treatment — a meaningful benchmark in a cancer that historically relapses again and again.
It signals access. China isn't just running trials. It's commercializing multiple BCMA CAR-T products and pairing them with insurance reform to get them to more patients.
It signals competition. Domestic Chinese biotech is now producing CAR-T therapies that rival, and in some specific metrics exceed, products approved in the US and Europe.
This article breaks down what that 64% figure actually means, which products are driving it, how China's outcomes stack up globally, and what it means if you're navigating a myeloma diagnosis or treatment decision in 2026.
What Is BCMA CAR-T Therapy?
Before the data makes sense, the mechanism needs to be clear.
CAR-T stands for chimeric antigen receptor T-cell therapy. Doctors extract a patient's own T-cells, genetically re-engineer them in a lab to recognize a specific target on cancer cells, multiply them by the billions, and infuse them back into the patient.
BCMA (B-cell maturation antigen) is the target. It's a protein expressed almost universally on malignant plasma cells in multiple myeloma — and barely anywhere else in the body. That specificity is what makes BCMA-targeted CAR-T so effective for myeloma compared with earlier, less targeted treatments.
Once infused, the re-engineered T-cells hunt down and destroy BCMA-expressing myeloma cells throughout the bone marrow. For many patients, this produces depth of response that older chemo-immunotherapy combinations simply can't match — including a high rate of minimal residual disease (MRD) negativity, the closest thing myeloma treatment has to a "no detectable cancer" reading.
The catch has always been durability: how long does that response last before the cancer escapes or relapses? That's exactly the question the 64% 12-month PFS figure is answering.
The 64% 12-Month PFS Number, Explained
"PFS" stands for progression-free survival — the percentage of patients who, at a defined time point, are alive and have not had their cancer progress.
A 64% 12-month PFS rate across China's domestically developed BCMA CAR-T programs means:
About 64 out of every 100 patients treated were progression-free a year after infusion.
This figure spans real-world, multi-center data — not a single best-case trial arm.
It sits in the same range as some of the strongest BCMA CAR-T results published anywhere in the world.
Context matters here. A widely cited meta-analysis of anti-BCMA CAR-T studies found a median progression-free survival of 14.0 months across 681 patients pooled from 22 studies, with an overall response rate around 85%. China's 64% 12-month PFS rate is consistent with — and in some specific domestic products, ahead of — that broader international picture.
It's also worth noting that PFS varies significantly by which CAR-T product, which patient population (newly diagnosed vs. heavily pretreated), and how many prior lines of therapy a patient has received. The 64% figure is a system-level signal of how far China's domestic programs have come — not a guarantee for any individual patient.
China's Domestic BCMA CAR-T Landscape in 2026
China now has several domestically developed, NMPA-approved or late-stage BCMA CAR-T products treating relapsed/refractory multiple myeloma (RRMM). The two most clinically mature are:
1. Equecabtagene Autoleucel (Fucaso / CT103A)
Developed by IASO Bio and Innovent, Fucaso was the first fully-human BCMA CAR-T therapy approved in China, receiving NMPA approval in June 2023 for relapsed or refractory multiple myeloma patients who had already received three or more prior lines of therapy.
In its pivotal FUMANBA-1 trial, equecabtagene autoleucel produced an overall response rate of 96% across 101 evaluable patients, including a 74.3% complete response or better rate. Among patients who hadn't had prior CAR-T exposure, the ORR climbed to 98.9%, with 78.7% achieving a complete response or better.
On durability, 12-month PFS rates were 78.8% for all patients, 89.5% for those who achieved a complete response or better, and 84.4% for patients who had previously received a different CAR-T product. Patients who sustained MRD negativity past 12 months had a 12-month PFS approaching 100%.
2. Ciltacabtagene Autoleucel (Carvykti, originally LCAR-B38M)
Originally developed in China by Legend Biotech under the name LCAR-B38M before global licensing, this product's long-term China-based data remains some of the most mature in the field. The four-year follow-up LEGEND-2 study found an overall response rate of 87.8%, with 73% of patients achieving a complete response and a median progression-free survival of 18.0 months.
It later returned to the Chinese market under regulatory approval for earlier-line treatment, supported by the CARTIFAN-1 trial, where 87.9% of patients responded, with a median progression-free survival of 30.13 months and overall survival not yet reached at nearly three years of follow-up.
3. Zevorcabtagene Autoleucel and Emerging Candidates
A newer wave of fully human BCMA CAR-T candidates, including zevorcabtagene autoleucel, is moving through Phase II trials across major Chinese hematology centers — from Beijing Chao-Yang Hospital to Sun Yat-sen University Cancer Center — expanding the domestic pipeline beyond the first two approved products.
Mini Case Study: Fucaso (Equecabtagene Autoleucel)
Fucaso is the clearest example of China's domestic BCMA CAR-T story playing out in real time.
The trajectory:
June 2023 — NMPA approval for fourth-line-and-beyond RRMM.
March 2024 — Expanded IND approval for second- and third-line treatment, based on data showing a 96.1% overall response rate and an 85.5% 12-month PFS rate among patients without prior CAR-T exposure.
Late 2024–2025 — Regulatory expansion outside mainland China, including Macau, Singapore, and a first-of-its-kind Hong Kong Department of Health approval — marking the first authorization of a China-developed CAR-T therapy in Hong Kong and the first China-developed advanced therapy medicinal product to receive PIC/S GMP recognition.
2025 — Real-world data from a single Chinese hematology center reinforced the trial findings, with the therapy already shown to achieve a 96% overall response rate in clinical trials, now being tracked across heterogeneous real-world patient populations including high-risk cytogenetics.
Why this matters beyond the spreadsheet: Fucaso's path shows a domestic Chinese biologic moving from local approval to regional international recognition in under three years — a pace that mirrors (and in some access metrics, beats) how Western-developed cell therapies have scaled globally.
Actionable insight: If you're evaluating treatment options in China or researching options for a loved one, ask specifically which CAR-T product is being proposed, what line of therapy it's approved for, and whether the treating center has reported its own outcome data — response rates and PFS can vary meaningfully between products and between centers.
How Domestic CAR-T Compares to Global Benchmarks
It's natural to ask: is China's "64% 12-month PFS" actually competitive, or just adequate?
Here's the honest comparison:
Metric | China Domestic (Pooled) | Global BCMA CAR-T Meta-Analysis | Carvykti (CARTIFAN-1, China) |
Overall Response Rate | 79–89% (B-cell malignancies) | 85.2% | 87.9% |
12-Month PFS | 64% | Median PFS: 14.0 months | Median PFS: 30.13 months |
Complete Response Rate | Varies by product | 47.0% | 79.3% |
MRD Negativity | High across leading products | 97.8% | Not separately reported |
The takeaway: China's aggregate domestic figure of 64% 12-month PFS represents a broad, system-wide average across multiple products and patient populations — including newer, less mature candidates. Individual flagship products like Fucaso and Carvykti, evaluated on their own, post higher 12-month PFS figures (78–89%) in their pivotal trials.
In other words, the 64% number is a conservative, real-world floor — not the ceiling. As more patients move onto the most mature domestic products and earlier lines of therapy, that aggregate PFS figure is likely to climb in future reporting cycles.
For deeper context on how myeloma treatment sequencing affects outcomes like this, see our https://www.chinacurelink.com/post/car-t-therapy-in-china-for-multiple-myeloma-2026-guide , which walks through where CAR-T fits relative to bispecific antibodies, transplant, and maintenance therapy.
Access, Cost, and the Insurance Pilot Changing Outcomes of Myeloma BCMA CAR-T
Efficacy data only matters if patients can actually get the treatment. This is where China's 2026 story gets genuinely interesting.
Regional insurance pilots are starting to close the affordability gap that has historically kept CAR-T out of reach for many myeloma patients. The Shanghai "Hu Hui Bao" pilot is the clearest example: it has cut patient out-of-pocket CAR-T costs by 41.7% and reimbursed over 33 million RMB in CAR-T-related treatment as of March 2024, while extending coverage to dozens of patients through a multi-tiered payment system spanning both urban and suburban institutions.
This matters because BCMA CAR-T has historically been a one-time, high-upfront-cost treatment — often a significant barrier even when clinically indicated. Insurance innovation, not just lab innovation, is becoming a core part of how China is scaling access to this therapy.
Practical tip for patients: If you're in China and being evaluated for CAR-T, ask your hospital's case management team directly whether your city or province has a regional CAR-T reimbursement pilot. Coverage varies significantly by location and is expanding quickly — what wasn't covered in 2024 may be partially reimbursed in 2026.
What Happens After CAR-T: Relapse, Retreatment, and Next Steps
No discussion of BCMA CAR-T is complete without addressing what happens when — not if, for many patients — the disease eventually progresses.
Roughly half of patients treated with BCMA CAR-T will experience relapse or progression within a few years, even after initial deep responses. A 2025 long-term follow-up study found that among responders, 75% remained relapse-free at a median follow-up of 23 months, with median progression-free survival and overall survival both reaching 35 months among that responder group — underscoring that durability is strongest in patients who respond well in the first place.
For patients who do relapse, sequential or retreatment strategies are an active area of research. One study on second BCMA CAR-T infusions after initial relapse found a 64.8% progression-free survival rate at six months following the second CAR-T treatment, with 100% of patients achieving at least a very good partial response — suggesting retreatment can still offer meaningful benefit, particularly when the first response was durable.
Newer fully human CAR-T constructs are also being studied specifically for patients who've already failed a prior BCMA CAR-T product. One such candidate showed a 71.4% overall response rate among patients who had previously progressed on anti-BCMA CAR-T therapy, with no severe neurotoxicity observed — a promising signal for the growing population of CAR-T-experienced myeloma patients.
Practical Guidance for Patients and Caregivers
If you're weighing BCMA CAR-T as an option in 2026, here's a grounded action checklist:
Ask which specific product is being recommended — Fucaso, Carvykti, or a trial candidate — and request that product's own published response and PFS data, not just the general "CAR-T" averages.
Confirm your line of therapy eligibility. Many domestic products are approved differently depending on how many prior treatments you've had; earlier-line approval can mean better outcomes.
Ask about MRD testing. Sustained MRD negativity is one of the strongest predictors of long-term PFS across nearly every study cited here.
Investigate regional insurance coverage before assuming cost is prohibitive — pilots are expanding faster than general awareness of them.
Discuss a relapse contingency plan up front. Ask your hematology team what the retreatment or next-line pathway looks like if CAR-T response doesn't hold, rather than waiting until progression occurs.
Where This Field Is Headed
A few trends worth watching through the rest of 2026:
Earlier-line approvals. Both Fucaso and Carvykti have moved, or are moving, toward second- and third-line approval rather than being reserved for heavily pretreated, fourth-line-and-beyond patients — and earlier treatment generally correlates with deeper, longer responses.
Cross-border expansion. Fucaso's approvals in Hong Kong, Macau, and pending review in Singapore suggest China's domestic CAR-T products are becoming exportable therapies, not just local solutions.
Bispecific CAR-T constructs. Dual-target approaches combining BCMA with CD38 are showing strong early efficacy signals in Chinese trials, aiming to reduce the antigen-escape relapses seen with single-target BCMA CAR-T.
Insurance-driven access expansion. Expect more cities to follow Shanghai's lead on CAR-T-specific reimbursement pilots, which will likely be the single biggest lever for improving real-world outcomes — since efficacy data only helps patients who can actually access the treatment.
Why International Patients Choose China
Many overseas patients seek treatment in China because of:
Specialized regenerative medicine centers
Experienced multidisciplinary diabetes teams
Advanced laboratory facilities
Personalized treatment protocols
Comprehensive international patient services
Competitive treatment pricing
Organizations like ChinaCureLink help international patients by:
Reviewing medical records
Identifying suitable hospitals
Coordinating physician consultations
Assisting with travel and medical logistics
Providing language support throughout treatment
This simplifies the treatment journey while helping patients make informed decisions based on their individual medical condition.
What Patients Say About ChinaCureLink & Medebound HEALTH
ChinaCureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials
FAQ: Frequently Asked Questions
What does "64% 12-month PFS" actually mean for a myeloma patient?
It means that, on average across China's domestic BCMA CAR-T programs, about 64% of treated patients were alive without disease progression one year after their infusion. It's a population-level statistic, not an individual prediction — your own outcome depends on your specific disease stage, prior treatments, and which CAR-T product you receive.
Which BCMA CAR-T therapies are approved in China right now?
The two most established are equecabtagene autoleucel (Fucaso, developed by IASO Bio and Innovent) and ciltacabtagene autoleucel (Carvykti, originally developed in China as LCAR-B38M by Legend Biotech). Several newer candidates, including zevorcabtagene autoleucel, are in late-stage trials.
How is Chinese domestic BCMA CAR-T different from US-approved products like Abecma or Carvykti?
Carvykti was actually originally developed in China before global licensing. China's newer domestic products, like Fucaso, are independently developed fully human BCMA CAR-T therapies with their own trial data, regulatory pathway, and increasingly, their own international approvals (Hong Kong, Macau, pending Singapore review).
Is BCMA CAR-T a cure for multiple myeloma?
No. Multiple myeloma remains, with current evidence, an incurable but increasingly manageable cancer. BCMA CAR-T produces deep, often MRD-negative responses, but a meaningful proportion of patients eventually relapse — which is why retreatment and sequencing strategies are an active research focus.
What happens if BCMA CAR-T stops working?
Options include a second BCMA CAR-T infusion (which has shown meaningful response rates in relapsed patients), newer CAR-T constructs designed for previously CAR-T-treated patients, bispecific antibodies, or other myeloma-directed therapies — the right path depends on how the relapse presents and whether BCMA expression is retained on the cancer cells.
Is BCMA CAR-T covered by insurance in China?
Coverage varies by region. Pilot programs like Shanghai's "Hu Hui Bao" have significantly reduced out-of-pocket costs for eligible patients, and similar reimbursement models are expanding to other cities. Ask your treatment center's case management team about local coverage specifics.
Key Takeaways
China's domestically developed BCMA CAR-T programs are now delivering a pooled 64% 12-month progression-free survival rate in multiple myeloma, alongside 79–89% overall response rates in B-cell malignancies broadly.
Leading individual products — Fucaso and Carvykti — post even higher 12-month PFS figures (78–89%) in their pivotal trials, suggesting the aggregate 64% figure is a conservative system-wide average.
Regulatory and insurance momentum (Hong Kong/Macau approvals, Shanghai's reimbursement pilot) is closing the access gap that has historically limited CAR-T's real-world impact.
Relapse remains a real possibility even after strong initial response, but retreatment and next-generation CAR-T constructs are showing encouraging results for patients who progress.
Patients and caregivers should ask specifically which product, which line of therapy, and which regional coverage options apply to their individual case — population averages don't replace a personalized conversation with a hematology-oncology team.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Comments